MARKETS
Analyst Actions

JP Morgan Reinstates Overweight on Immunocore Holdings, Announces $50 Price Target

Aug 21, 2026 · 03:08 PM ET· updated 1h ago

JP Morgan analyst Jessica Fye reinstates Immunocore Holdings (NASDAQ:IMCR) with a Overweight and announces $50 price target.

Share
Why It Matters

A big investment bank's expert says Immunocore is worth watching and could do well. This means the expert thinks the company has a good chance to grow, so people might pay closer attention to what happens with it next.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.